Is the human T-cell lymphotropic virus type 2 in the process of endogenization into the human genome?
Endogenization
HTLV-2
Human retroviruses
Viral pathogenicity
Journal
Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
15
11
2019
revised:
27
08
2020
accepted:
27
08
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
Human T-cell lymphotropic virus type 2 (HTLV-2) infection has been shown to be endemic among intravenous drug users in parts of North America, Europe and Southeast Asia and in a number of Amerindian populations. Despite a 65% genetic similarity and common host humoral response, the human T-cell lymphotropic viruses type 1 (HTLV-1) and 2 display different mechanisms of host interaction and capacity for disease development. While HTLV-1 pathogenicity is well documented, HTLV-2 etiology in human disease is not clearly established. From an evolutionary point of view, its introduction and integration into the germ cell chromosomes of host species could be considered as the final stage of parasitism and evasion from host immunity. The extraordinary abundance of endogenous viral sequences in all vertebrate species genomes, including the hominid family, provides evidence of this invasion. Some of these gene sequences still retain viral characteristics and the ability to replicate and hence are potentially able to elicit responses from the innate and adaptive host immunity, which could result in beneficial or pathogenic effects. Taken together, this data may indicate that HTLV-2 is more likely to progress towards endogenization as has happened to the human endogenous retroviruses millions of years ago. Thus, this intimate association (HTLV-2/human genome) may provide protection from the immune system with better adaptation and low pathogenicity.
Identifiants
pubmed: 33294211
doi: 10.1016/j.jve.2020.100009
pii: S2055-6640(20)31458-8
pmc: PMC7695812
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100009Informations de copyright
© 2020 The Authors.
Références
Lancet. 1990 Sep 1;336(8714):575-6
pubmed: 1975077
Virology. 1998 Apr 10;243(2):366-79
pubmed: 9568035
Viruses. 2016 Jan 27;8(2):
pubmed: 26828513
Sci Rep. 2015 Feb 02;5:8164
pubmed: 25641657
Annu Rev Virol. 2015 Nov;2(1):135-59
pubmed: 26958910
Hum Reprod. 2007 Nov;22(11):2868-78
pubmed: 17855413
AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):407-17
pubmed: 10195750
PLoS One. 2011;6(12):e28586
pubmed: 22194862
Nucleic Acids Res. 2011 Jan;39(Database issue):D70-4
pubmed: 21036865
J Cell Biol. 1994 Nov;127(4):903-14
pubmed: 7962075
Front Microbiol. 2014 Jul 29;5:398
pubmed: 25120538
J Immunol. 2014 Aug 15;193(4):1544-8
pubmed: 25024383
J Virus Erad. 2018 Jul 1;4(3):174-178
pubmed: 30050680
Nat Rev Immunol. 2016 Apr;16(4):207-19
pubmed: 27026073
Iran J Basic Med Sci. 2013 Mar;16(3):179-95
pubmed: 24470860
Ann N Y Acad Sci. 2009 Oct;1178:157-72
pubmed: 19845636
AIDS Res Hum Retroviruses. 1994 Sep;10(9):1165-71
pubmed: 7826700
AIDS Res Hum Retroviruses. 1995 May;11(5):637-45
pubmed: 7576920
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):100-6
pubmed: 16340481
Mol Biol Evol. 2000 Mar;17(3):374-86
pubmed: 10723738
Gene. 1999 Jun 24;234(1):11-21
pubmed: 10393234
EMBO J. 1990 Dec;9(13):4243-8
pubmed: 2124968
J Virol. 2016 Jan 27;90(7):3760-72
pubmed: 26819304
PLoS Pathog. 2007 Nov;3(11):e170
pubmed: 17997604
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Retrovirology. 2017 Aug 22;14(1):41
pubmed: 28830571
Retrovirology. 2019 Sep 6;16(1):25
pubmed: 31492165
Retrovirology. 2017 Apr 26;14(1):27
pubmed: 28446240
Virology. 1993 Dec;197(2):576-84
pubmed: 8249280
Viral Immunol. 2011 Dec;24(6):429-39
pubmed: 22111594
Oncogene. 2015 Jan 15;34(3):334-45
pubmed: 24362528
Scand J Immunol. 2007 Jun;65(6):577-80
pubmed: 17523951
J Virol. 1998 Jan;72(1):841-6
pubmed: 9420297
J Virol. 2012 Apr;86(7):3757-66
pubmed: 22278223
Philos Trans R Soc Lond B Biol Sci. 2010 Aug 27;365(1552):2487-94
pubmed: 20643738
Clin Infect Dis. 2004 Jul 15;39(2):256-63
pubmed: 15307036
Mol Biol Evol. 2001 Apr;18(4):661-71
pubmed: 11264418
Nat Rev Genet. 2012 Mar 16;13(4):283-96
pubmed: 22421730
Rev Inst Med Trop Sao Paulo. 2015 Jan-Feb;57(1):1-13
pubmed: 25651320
Oncogene. 2005 Sep 5;24(39):5926-30
pubmed: 16155599
Front Microbiol. 2013 Sep 17;4:275
pubmed: 24062732
Nature. 1981 Nov 19;294(5838):268-71
pubmed: 6272125
Oncogene. 2005 Sep 5;24(39):6058-68
pubmed: 16155612
Nature. 2006 Jul 6;442(7098):79-81
pubmed: 16823453
Virology. 2015 May;479-480:26-37
pubmed: 25771486
J Emerg Med. 2000 Jan;18(1):109-19
pubmed: 10645850
Oncogene. 2005 Sep 5;24(39):5996-6004
pubmed: 16155606
Rev Inst Med Trop Sao Paulo. 2006 Jul-Aug;48(4):207-10
pubmed: 17119676
Virology. 1996 Mar 1;217(1):373-9
pubmed: 8599225
Leuk Res Treatment. 2012;2012:876153
pubmed: 23213551
Microbiol Mol Biol Rev. 2017 Dec 13;82(1):
pubmed: 29237726
Future Virol. 2008 Sep;3(5):481-490
pubmed: 19578477
Am J Trop Med Hyg. 1993 Dec;49(6):657-63
pubmed: 8279632
APMIS. 2016 Jan-Feb;124(1-2):4-10
pubmed: 26818257